Here are four things to know.
- MEDI2070 is an anti-inflammatory drug undergoing clinical trials for the treatment of Crohn’s disease and ulcerative colitis.
- Parsippany-Troy Hills, N.J.-based Allergan purchased the exclusive global rights to MEDI2070 for an upfront payment of $250 million, with the potential for future milestone payments of up to $1.27 billion.
- Gaithersburg, Md.-based MedImmune is developing MEDI2070 through a collaboration agreement with Amgen, headquartered in Thousand Oaks, Calif. London-based AstraZeneca will give Amgen one-third of the royalties it receives from Allergan.
- The deal is expected to close in the fourth quarter of 2016.
More articles on supply chain:
Supply chain tip of the week: Use data to motivate change
Drugmakers bid on Bayer’s dermatology division
3 ways augmented reality devices could improve supply chain
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
